’Omics’ in Chronic Liver Disease

Description

The 'omics' revolution offers a gateway to a new level of precision medicine in chronic liver disease.  In this session, we highlight  six outstanding examples of genomic and metabolic explorations into the pathogenesis and diagnosis of HCC and MASLD.

Presentations

11:00 AM - 11:15 AM
Apr 29 2026
Washington, D.C.

Integration Across Primary Liver Tumors Identifies Clinically Relevant Molecular Subtypes of HCC

Renumathy Dhanasekaran, MD, PhD , Abstract Presenter
Basic Science
Liver Cancer
MASLD

Objectives

  • Discuss genomic advances impacting our understanding of the mechanisms of hepatocarinogenesis.
  • Identify novel targets for future therapeutic interventions in hepato-biliary cancers.
  • Recognize new metabolic pathways involved in MASLD.